ARDT Ardent Health Partners, Inc.

NYSE ardenthealth.com


$ 8.91 $ 0.33 (3.84 %)    

Monday, 17-Nov-2025 11:50:33 EST
QQQ $ 610.60 $ 4.48 (0.74 %)
DIA $ 471.63 $ 0.77 (0.16 %)
SPY $ 672.54 $ 2.84 (0.42 %)
TLT $ 89.27 $ 0.19 (0.21 %)
GLD $ 374.18 $ 0.18 (0.05 %)
$ 9.01
$ 8.70
$ 8.89 x 1
$ 8.92 x 1
$ 8.57 - $ 9.01
$ 8.85 - $ 17.91
1,924,929
na
1.29B
$ 0.33
$ 6.29
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Keybanc analyst Matthew Gillmor downgrades Ardent Health (NYSE:ARDT) from Overweight to Sector Weight.

Core News & Articles

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and lowers the price target from $21 t...

Core News & Articles

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and lowers the price target from $2...

Core News & Articles

Stephens & Co. analyst Scott Fidel maintains Ardent Health (NYSE:ARDT) with a Overweight and lowers the price target fr...

Core News & Articles

Morgan Stanley analyst Craig Hettenbach downgrades Ardent Health (NYSE:ARDT) from Overweight to Equal-Weight and lowers the ...

Core News & Articles

B of A Securities analyst Kevin Fischbeck maintains Ardent Health (NYSE:ARDT) with a Underperform and lowers the price targe...

Core News & Articles

Ardent Health (NYSE:ARDT) lowers FY2025 GAAP EPS guidance from $1.73-$2.01 to $0.85-$1.03 vs $1.85 analyst estimate. Affirms FY...

Core News & Articles

Ardent Health Partners (NYSE:ARDT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate o...

Core News & Articles

Goldman Sachs analyst Scott Fidel initiates coverage on Ardent Health (NYSE:ARDT) with a Neutral rating and announces Price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION